Tolvaptan-d7

Tolvaptan-d7

• CAS Number: 1246818-18-7
• UNSPSC Description: Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].
• Target Antigen: Autophagy; Isotope-Labeled Compounds; Vasopressin Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;GPCR/G Protein;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Cardiovascular Disease; Endocrinology; Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=C(C=C(C=C1)NC(C2=C(C([2H])=C([2H])C([2H])=C2[2H])C([2H])([2H])[2H])=O)C)N3C4=CC=C(Cl)C=C4C(CCC3)O
• Molecular Weight: 455.98
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Friedman B, Cirulli J.
 Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan.
 J Crit Care. 2012 Aug 8.|[3]Inomata T.
 Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11.|[4]Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.
 Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
 J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22.|[5]Y Yamamura et al. OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. J. Pharmacol. 
 Exp. Ther. 1998, 287(3), 860-867.|[6]RW Schrier et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006, 355, 2099-2112.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported